← Eichor
Study identifier: NCT05064319 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

Condition: Bipolar Disorder · Cannabis Use · Schizoaffective Disorder, Bipolar Type  ·  Sponsor: Medical University of South Carolina

PhasePhase 2
Planned participants68
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

This research study evaluates the effects of an FDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be assigned to take either Gabapentin or a matched placebo. Study medication will be taken for 17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.

This description comes directly from the study's public registry record.

Talk to the study team

Sara Hix  ·  843-792-7500  ·  hixs@musc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Medical University Of South CarolinaCharleston, South Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05064319